Korean FDA grants pre-market clearance for ETView's VivaSight‐SL airway management solutions

ETView (TASE: ETVW) today announced that the Korean Food and Drug Administration ("KFDA") has granted pre-market clearance for VivaSight™‐SL. With KFDA clearance, ETView plans to immediately initiate market launch of VivaSight™‐SL. ETView also announced a distribution agreement with ChinooMTech Company (Seoul). The agreement enables ChinooMTech to market ETView's VivaSight™ platform (previously known as TVT™), combining an airway ventilation tube with integrated continuous high resolution airway imaging for patient airway control and lung isolation capability in Korea for a period of 2 years.

“We are excited to add ChinooMTech to our expanding distributor network.”

William Edelman, CEO of ETView Medical, commented, "We are excited to add ChinooMTech to our expanding distributor network." Mr. Edelman continued, "VivaSight™‐SL is currently being distributed across Europe and the United States. With a population of over 48 million, Korea represents an important healthcare market. With KFDA clearance, we believe that VivaSight™‐SL will provide best-in-class airway management solutions for sophisticated thoracic surgical procedures requiring lung isolation."